

Substitute for Form 1449/PTO			Complete if Known Application Number: 10/038,557 Filing Date: January 3, 2002 First Named Inventor: Terry M. Fredeking Art Unit: 1617 Examiner Name: Chong, Yong Soo Attorney Docket Number: 007841.P001D2	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				
Sheet	1	of	3	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If known)				
		US-	4,390,623	06-28-1983	Frabricius et al.	
		US-	4,935,411	06-19-1990	McNamara et al.	
		US-	5,045,538	09-03-1991	Schneider et al.	
		US-	5,459,135	10-17-1995	Golub et al.	
		US-	5,834,449	11-10-1998	Thompson et al.	
		US-	5,919,775	07-06-1999	Amin et al.	
		US-	5,929,055	07-27-1999	Ryan et al.	
		US-	5,977,091	11-02-1999	Nieman et al.	
		US-	5,998,390	12-07-1999	Ramamurthy et al.	
		US-	6,015,804	01-18-2000	Golub et al.	
		US-	6,043,231	03-28-2000	Pruzanski et al.	
		US-	6,100,248	08-08-2000	Golub et al.	
		US-	6,114,316	09-05-2000	Ramamurthy et al.	
		US-	6,277,061 B1	08-21-2001	Golub et al.	
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examine r Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹

Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Based on PTO/SB/08A (08-03) as modified by Blakely, Sokoloff, Taylor & Zafman, (wtr) 08/11/2003.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/038,557	
			Filing Date	January 3, 2002	
			First Named Inventor:	Terry M. Fredeking	
			Art Unit	1617	
			Examiner Name	Chong, Yong Soo	
Sheet	2	of	3	Attorney Docket Number	007841.P001D2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Breedveld et al., "Minocycline Treatment for Rheumatoid Arthritis: An Open Dose Fining Study," J. Rheumatol., 1990, pp. 43-46, 17.	
		"Progress with Multiple Sclerosis: Control through inhibition of TNF-α production," Cytokine Bulletin, Fall 1995, page 2.	
		"The Immune System and Parkinson's Disease: Focus on Inflammatory Cytokines," Parkinson's Disease UPDATE Newsletter, Reprint from UPDATE Newsletter, Issue #54, 1995, http://www.chronicillnet.org/new/PD_update.html (2/19/01).	
		Maurer et al., "Genetic variation at position -1082 of the interleukin 10 (IL10) promoter and the outcome of multiple sclerosis," J. of Neuroimmunology, 2000, pp. 98-100, 104.	
		Nagelkerken, L., "Role of Th1 and Th2 cells in autoimmune demyelinating disease," Brazilian Journal of Medical and Biological Research, 1998, pp. 55-60, 31.	
		Ozenci et al., "Multiple Sclerosis: Levels of Interleukin-10-Secreting Blood Mononuclear Cells are Low in Untreated Patients but Augmented During Interferon-β-1b Treatment," Scand. J. Immunol., 1999, pp. 554-561, 49.	
		Salmaggi et al., "Low serum interleukin-10 levels in multiple sclerosis: further evidence for decreased systemic immunosuppression?" J. Neurol., 1996, pp. 13-17, 243.	
		van Deuren M., "Kinetics of Tumor necrosis factor-alpha, soluble tumor necrosis factor receptors, Interleukin 1-beta and its receptor antagonist during serious infections," Eur. J. Clin. Microbiol., Infect Dis. Supplement 1, 1994, pp. 12-16, 13.	
		Conti et al., "MCP-1 and RANTES are mediators of acute and chronic inflammation," Allergy Asthma Proc., 2001, pp. 133-137, 22(3).	
		Piet et al., "The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation," Transfusion, 1990, pp. 591-598, 30(7).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹

Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Based on PTO/SB/08A (08-03) as modified by Blakely, Sokoloff, Taylor & Zafman, (wir) 08/11/2003.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Y.C./

